

# The effect of ultraviolet radiation on the skin manifestations of patients with dermatomyositis.

Gepubliceerd: 05-09-2005 Laatst bijgewerkt: 18-08-2022

N/A

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving gestopt
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON22361

### Bron

NTR

### Verkorte titel

N/A

### Aandoening

Dermatomyositis

## Ondersteuning

**Primaire sponsor:** Dept of Dermatology/Allergology

University Medical Centre  
Heidelberglaan 100, G02.124  
3584CX Utrecht  
Netherlands

**Overige ondersteuning:** None

## Onderzoeksproduct en/of interventie

## **Uitkomstmaten**

### **Primaire uitkomstmaten**

In summary, we will determine the initial cutaneous response after UVB provocation of the skin. Specifically we will determine the trafficking of Langerhans cell, leucocytes and lymphocytes and the expression of MMP in skin lesions and compare these with healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption, for which the results have already been obtained.

## **Toelichting onderzoek**

### **Achtergrond van het onderzoek**

In summary, we will determine the initial cutaneous response after UVB provocation of the skin. Specifically we will determine the trafficking of Langerhans cell, leucocytes and lymphocytes and the expression of MMP in skin lesions and compare these with healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption, for which the results have already been obtained.

### **Doel van het onderzoek**

N/A

### **Onderzoeksopzet**

N/A

### **Onderzoeksproduct en/of interventie**

In summary, we will use our phototest protocol for patients with DM;

1. To determine the minimal erythema dose (MED) for UVB, UVA, and visible light.
2. To determine the clinical aspect of the photoprovoked skin lesions.
3. To determine the time interval between the start of phototesting and induction of skin lesions until their resolution.
4. To record any adverse events.

The information thus acquired can be used to advise the patient more specifically on appropriate protection measures that can be taken against environmental UV radiation.

B. Determination of the cellular trafficking in the initial cutaneous inflammation induced by photoprovocation in patients with DM

After determination of the MED for UVB a test area of 5 cm square on the upper back will be exposed to 3 MED UVB.

Skin biopsies (4 mm.) will be taken of the test area at 0, 24, 48 and 72 hours after one single UVB exposure with 3 MED.

These skin biopsies will be compared with those of healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption. The results for these groups have already been obtained.

## Contactpersonen

### Publiek

University Medical Center Utrecht (UMCU),  
Department of Dermatology/Allergology,  
G02.124,  
Heidelberglaan 100  
Cornelus J.G. Sanders  
Heidelberglaan 100

Utrecht 3584 CX  
The Netherlands

### Wetenschappelijk

University Medical Center Utrecht (UMCU),  
Department of Dermatology/Allergology,  
G02.124,  
Heidelberglaan 100  
Cornelus J.G. Sanders  
Heidelberglaan 100

Utrecht 3584 CX  
The Netherlands

## Deelname eisen

## **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Patients with DM that have been diagnosed according to international accepted guidelines (1-3);
2. The medication that is used by the patients specifically for DM or other related symptoms will be continued during phototesting;
3. The patients should not use corticosteroid creams or sunscreens during phototesting;
4. Patients with DM are invited to participate in this study and are included after signed informed consent is obtained.

## **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

Any malignancy for which the patient is treated with cytostatic drugs and/or radiotherapy.

## **Onderzoeksopzet**

### **Opzet**

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Enkelblind
Controle:	Geneesmiddel

### **Deelname**

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	24-09-2004
Aantal proefpersonen:	10
Type:	Werkelijke startdatum

## Ethische beoordeling

Positief advies

Datum: 05-09-2005

Soort: Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

Register	ID
NTR-new	NL146
NTR-old	NTR181
Ander register	: N/A
ISRCTN	ISRCTN35411849

## Resultaten